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Objectives: To assess the effect of vitamin D supplementation on bone mineral density
(BMD) in rheumatoid arthritis (RA) patients with osteoporosis and determine whether
supplementation of more than 800 IU/day, which is the currently recommended dose,
is beneficial.
Methods: RA patients with osteoporosis who received bisphosphonate were included.
Patients were classified into four groups according to the dose of vitamin D
supplementation (0, 400, 800, and≥1,000 IU/day). Multivariable linear regressionmodels
were performed to evaluate the effect of each dose of vitamin D supplementation on
1-year% change of BMD.
Results: In total, 187 RA patients with osteoporosis were included. In the multivariate
model adjusted for potential confounders, patients receiving vitamin D supplementation
had a significantly higher increase in 1-year % change in lumbar spine BMD (400 IU/day:
β = 2.51 [95% CI: 0.04–4.99], 800 IU/day: β = 2.90 [95% CI: 0.47–5.33], and ≥1,000
IU/day: β = 6.01 [95% CI: 3.71–8.32]) and femoral neck BMD (400 IU/day: β = 3.88
[95% CI: 1.83–5.94], 800 IU/day: β =4.30 [95% CI: 2.25–6.35], and ≥1,000 IU/day: β
= 6.79 [95% CI: 4.87–8.71]) than those not receiving the supplementation. Notably, the
≥1,000-IU/day group had a significantly higher increase in 1-year % change in lumbar
spine BMD (β = 3.11 [95% CI: 0.86–5.37]) and femoral neck BMD (β = 2.50 [95% CI:
0.63–4.36]) than the 800-IU/day group.
Conclusion: In RA patients with osteoporosis receiving bisphosphonates, vitamin D
supplementation was associated with a higher increase in BMD. This effect was higher
in the vitamin D supplementation dose of ≥1,000 IU/day than in 800 IU/day.
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INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammatory
arthritis (1). Since RA is a disease in which long-term glucocorticoid is commonly used (1),
glucocorticoid-induced osteoporosis (GIOP) is an important comorbidity that needs to be
considered when treating patients with RA. Indeed, population-based studies have reported a
higher risk of osteoporosis in patients with RA (2, 3).
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In the 2017 American College of Rheumatology guideline
for the prevention and treatment of GIOP, a vitamin D intake
of 600–800 IU/day has been recommended (4). Similarly,
the Korean guideline for the prevention and treatment of
GIOP also recommends a vitamin D intake of 800 IU/day
(5). However, the recommended vitamin D intake of 600–
800 IU/day is based on general population data, rather than
those of patients with specific diseases, including RA, who
require long-term glucocorticoid therapy (6). Due to the
indirectness of the evidence, a vitamin D intake of 600–
800 IU/day is only conditionally recommended in the GIOP
guideline (4). Currently, data about the effect of vitamin
D supplementation on bone mineral density (BMD) in RA
patients with osteoporosis are limited, and the optimal dose of
supplementation remains unclear.
Osteoporosis is characterized by low BMD and
microarchitectural deterioration of the bone tissues, leading
to an increased risk of fracture (7). Vitamin D affects the rate
of bone turnover and the overall mineralization of the bone.
Thus, vitamin D deficiency is associated with a higher bone
turnover and incidence of fracture (8). Considering that vitamin
D deficiency is highly prevalent in RA patients (9, 10), the
required dose of vitamin D supplementation in RA patients with
osteoporosis might be higher than the recommended intake of
600–800 IU/day (4), which is based on general population data.
This study aimed to assess the effect of vitamin D
supplementation on BMD in RA patients with osteoporosis and
to determine whether a dose higher than 800 IU/day is more
effective in improving BMD in patients with RA.
PATIENTS AND METHODS
Study Population
Electronic medical records of RA patients who were newly
diagnosed with osteoporosis and who started receiving
bisphosphonates at two tertiary referral hospitals in Seoul,
South Korea, between 2013 and 2017 were retrospectively
reviewed. All patients met the 2010 American College
of Rheumatology/European League Against Rheumatism
classification criteria for RA (11). A diagnosis of osteoporosis
was made based on the following BMD results: lumbar spine
T-score ≤−2.5 and/or femoral neck T-score ≤−2.5. Patients
who were taking medications other than bisphosphonates
(selective estrogen receptor modulators, and teriparatide) for the
treatment of osteoporosis, those with metabolic diseases, such
as thyroid and parathyroid diseases, that can affect BMD, those
with a history of previous fracture, and those who were current
smokers were excluded.
This study was approved by the Institutional Review Board
(IRB) of Gangnam Severance Hospital (IRB No: 3-2020-0043)
and Asan Medical Center in Seoul, South Korea (IRB No: 2018-
0090). Requirement of informed consent was waived because of
the retrospective nature of the study.
BMD Assessment and Outcome Variables
BMDs of the lumbar spine (first to fourth vertebrae) and femoral
neck were evaluated using dual-energy X-ray absorptiometry (GE
Healthcare Lunar or Hologic system) (12). As per the insurance
policy in our country, BMD was assessed annually (i.e., for
insurance coverage, BMD data must be obtained every year). The
same instrument was used for repeat BMDmeasurement in each
patient. The BMD results of theHologic systemwere converted to
GEHealthcare Lunar BMD results using the conversion equation
(13). Data about BMD results at the diagnosis of osteoporosis and
after 1 year of treatment were collected for analysis. Outcome
variables were 1-year % change in lumbar spine and femoral
neck BMDs.
Vitamin D Supplementation
The average dietary intake of vitamin D is relatively low in South
Korea (male: 160 IU/day, and female: 104 IU/day) (14), and as
the majority of vitamin D intake comes from supplementation
rather than diet, we focused on the dose of supplementation
of vitamin D. Vitamin D supplements were in the form of
calcium–vitamin D complex tablet or bisphosphonate–vitamin
D complex tablet. Each tablet contained a specific amount of
vitamin D [calcium–vitamin D complex for daily use: 400, 800,
and 1,000 IU/tablet; bisphosphonate–vitamin D complex for
weekly use: 5,600 IU/tablet [equivalent to 800 IU/day] (15); or
bisphosphonate–vitamin D complex for monthly use: 24,000
IU/tablet [equivalent to 800 IU/day] (15)]. Thus, the vitamin D
supplementation dose was used as a categorical variable rather
than a continuous variable. The type of vitamin D supplement
was chosen based on the treating physicians’ preference. Patients
were classified into four groups according to the dosage of
vitamin D supplementation, which were as follows: 0, 400, 800,
and ≥1,000 IU/day. As calcium supplementation was provided
in the form of calcium–vitamin D complex tablet, the 0-IU/day
group also did not receive any calcium supplementation, whereas
the other three groups received 500–1,000 mg/day of calcium
supplementation in the form of calcium–vitamin D complex
tablet. The average dietary intake of calcium in South Korea
is 542 mg/day (16). Therefore, the total calcium intake (total
of diet and supplementation) of patients receiving vitamin
D supplementation was ∼1,000–1,500 mg/day, which was in
accordance with the recommended calcium intake of 1,000–1,200
mg/day (4).
Covariates
At the time of diagnosis of osteoporosis, the following data
were collected: age, sex, body mass index (BMI), positivity
to rheumatoid factor (RF) and anti-cyclic citrullinated peptide
(CCP) antibody, and disease activity score 28 with erythrocyte
sedimentation rate (DAS28-ESR). Data about medications
prescribed during the 1-year interval between the BMD
tests, including cumulative dose of glucocorticoid, use of
conventional synthetic disease-modifying anti-rheumatic drugs
(csDMARDs) and biologic DMARDs (bDMARDs), and type of
bisphosphonate, were reviewed. For glucocorticoid use, the total
glucocorticoid dose prior to the initial BMD test, and the current
status (users or not) of glucocorticoid use at the initial BMD test
were also reviewed.
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Statistical Analysis
To compare the different groups, ANOVA was used for
continuous variables and the chi-square test (when <20% of
cells had expected count <5) or Fisher’s exact test (when
20% or more cells had expected count <5) was used for
categorical variables. Multivariable linear regression analyses
were performed to assess the effect of vitamin D supplementation
on 1-year % changes in BMD. For each category of vitamin
D supplementation dosage, we estimated the mean difference
(effect estimate [β] and 95% confidence interval [CI]) in 1-
year % changes in BMD between patients with and without
vitamin D supplementation. Potential confounders, such as age,
sex, BMI, total glucocorticoid dose prior to the initial BMD test,
cumulative glucocorticoid dose between BMD measurements,
use of csDMARDs and bDMARDs, DAS28-ESR, and type of
bisphosphonate, were adjusted in the multivariable models using
enter method. The variation inflation factor (VIF) was assessed
to exclude multicollinearity among covariates included in the
multivariable analyses. VIFs of all covariates were less than 5,
confirming the absence of multicollinearity. The normality of the
residual was tested using a histogram and normal P–P plot of
the regression standardized residual, and the homoscedasticity
of the residual was assessed using the scatter plot: the residual
followed a normal distribution and was homoscedastic. Further,
to evaluate whether a vitamin D supplementation dose of >800
IU/day is more effective than that of 800 IU/day in terms of
improving BMD, the mean difference in 1-year % change in
BMD between the ≥1,000- and 800-IU/day groups was assessed.
P < 0.05 was considered statistically significant. All analyses
were conducted using the SPSS software (version 25.0; IBM
Corporation, Armonk, NY, USA).
RESULTS
Comparison Among the Different Vitamin D
Supplementation Dose Groups
A total of 286 patients with RA, who were newly diagnosed with
osteoporosis, were identified. Thirty-two patients who received
medication other than bisphosphonate (selective estrogen
receptor modulators: 30 patients, and teriparatide: 2 patients) for
the treatment of osteoporosis, 14 patients with thyroid disease,
2 patients with parathyroid disease, 12 patients with a history
of previous fracture, and 39 patients who were current smoker
were excluded. The remaining 187 RA patients with osteoporosis
were included in the analysis. Sixty-one patients did not receive
vitamin D supplementation (0-IU/day group), whereas 23, 73,
and 30 patients received vitamin D supplementation at a dose of
400 IU/day (400-IU/day group), 800 IU/day (800-IU/day group),
and ≥1,000 IU/day (≥1,000-IU/day group), respectively. In the
≥1,000-IU/day group, 26 (86.7%) patients received 1,000 IU/day,
one (3.3%) patient received 1,200 IU/day, and three (10.0%)
patients received 1,800 IU/day. Comparison results among the
different groups are shown in Table 1. The four groups did not
differ in terms of age (p = 0.641), sex distribution (p = 0.570),
BMI (p = 0.915), positivity to RF (p = 0.633) and anti-CCP
antibody (p = 0.248), total glucocorticoid dose prior to the
initial BMD test (p= 0.605), proportion of current glucocorticoid
users (p = 0.109), cumulative dose of glucocorticoid between
BMD tests (p = 0.246), use of csDMARDs (methotrexate, p
= 0.416; hydroxychloroquine, p = 0.752; sulfasalazine, p =
0.731; leflunomide, p = 0.621; and tacrolimus, p = 0.946)
and bDMARDs (tumor necrosis factor inhibitor, p = 0.134;
tocilizumab, p = 0.610; and abatacept, p = 0.851), and DAS28-
ESR (p = 0.846). The type of bisphosphonate used (risedronate:
p < 0.001, alendronate: p < 0.001, and ibandronate: p = 0.001)
was different among the groups (Table 1).
According to the initial BMD, 94 (50.3%) patients had
osteoporosis in the lumbar spine, 33 (17.6%) patients had
osteoporosis in the femoral neck, and 60 (32.1%) patients had
osteoporosis in both lumbar spine and femoral neck. The initial
lumbar spine T-score (p = 0.737) and initial femoral neck T-
score (p = 0.252) did not differ among the four groups. The
mean values of 1-year % changes in the lumbar spine BMD and
femoral neck BMD in the total study population were 3.92 and
1.19%, respectively. The 1-year % change of lumbar spine BMD
(p <0.001) and femoral neck BMD (p <0.001) was significantly
different among groups (Table 1 and Figure 1).
Effect of Vitamin D Supplementation on
1-year % Changes in BMD
The results of linear regression analyses are shown inTable 2. The
overall p value for the regression was p <0.001 for all univariable
and multivariable analyses. The total amount of variance
explained in the univariable and in the multivariable analyses
was as follows: univariable (lumbar spine), 0.210; multivariable
(lumbar spine), 0.298; univariable (femoral neck), 0.281; and
multivariable (femoral neck), 0.370. In the multivariable analysis,
the 1-year % change in lumbar spine BMD was significantly
higher in the vitamin D supplementation groups (400 IU/day:
β = 2.51 [95% CI 0.04–4.99], p = 0.047; 800 IU/day: β =
2.90 [95% CI 0.47–5.33], p = 0.020; and ≥1,000 IU/day: β
= 6.01 [95% CI 3.71–8.32], p <0.001) than in the 0-IU/day
group. Similarly, the supplementation of vitamin D, regardless of
dose, was significantly associated with a higher 1-year % change
in femoral neck BMD (400 IU/day: β = 3.88 [95% CI 1.83–
5.94], p <0.001; 800 IU/day: β = 4.30 [95% CI 2.25–6.35], p
<0.001; and ≥1,000 IU/day: β = 6.79 [95% CI 4.87–8.71], p
<0.001) (Table 2). Coefficients and their significance levels of
all variables included in the multivariable analysis are shown in
Supplementary Table 1.
Comparison of 1-year % Changes in BMD
Between the ≥1,000- and 800-IU/day
Groups
In the multivariable linear regression analysis comparing the
effects of ≥1,000 and 800 IU/day, a vitamin D supplementation
of≥1,000 IU/day was associated with a significantly higher 1-year
% change in lumbar spine BMD (β = 3.11 [95% CI 0.86–5.37], p
= 0.007) and femoral neck BMD (β = 2.50 [95% CI 0.63–4.36], p
= 0.009) (Table 3).
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TABLE 1 | Characteristics of patients (n = 187) according to the dose of vitamin D supplementation.
0 IU/day 400 IU/day 800 IU/day ≥1,000 IU/day P
(n = 61) (n = 23) (n = 73) (n = 30)
Age (years), mean ± SD 65.7 ± 8.9 65.7 ± 9.3 64.0 ± 8.5 64.1 ± 8.7 0.641
Female, n (%) 58 (95.1) 22 (95.7) 65 (89.0) 27 (90.0) 0.570F
BMI (kg/m2 ), mean ± SD 22.7 ± 3.2 23.0 ± 3.9 23.1 ± 3.1 22.9 ± 3.5 0.915
RF positive, n (%) 45 (73.8) 18 (78.3) 60 (82.2) 22 (73.3) 0.633X
Anti-CCP Ab positive, n (%) 45 (73.8) 19 (82.6) 62 (84.9) 21 (70.0) 0.248X
Total glucocorticoid dose prior to the initial 1612.5 (210.0–2033.8) 1435.0 (330.0–2570.0) 1035.0 (275.0–1922.5) 1762.5 (343.1–3490.0) 0.605
BMD test (mg), median (IQR)
Current glucocorticoid users, n (%) 57 (93.4) 21 (91.3) 58 (79.5) 27 (90.0) 0.109
Glucocorticoida (mg), mean ± SD 1295.2 ± 731.3 1218.1 ± 651.4 1022.2 ± 841.8 1172.3 ± 842.3 0.246
USE OF CSDMARDS, N (%)
MTX 52 (85.2) 19 (82.6) 67 (91.8) 25 (83.3) 0.416F
HCQ 28 (45.9) 8 (34.8) 30 (41.1) 11 (36.7) 0.752X
SSZ 12 (19.7) 7 (30.4) 15 (20.5) 6 (20.0) 0.731X
LEF 9 (14.8) 5 (21.7) 9 (12.3) 3 (10.0) 0.621F
TAC 4 (6.6) 2 (8.7) 4 (5.5) 2 (6.7) 0.946F
USE OF BDMARDS, N (%)
TNFi 1 (1.6) 0 (0.0) 6 (8.2) 3 (10.0) 0.134F
Tocilizumab 1 (1.6) 0 (0.0) 0 (0.0) 0 (0.0) 0.610F
Abatacept 2 (3.3) 0 (0.0) 1 (1.4) 0 (0.0) 0.851F
DAS28-ESR, mean ± SD 3.19 ± 1.04 3.11 ± 0.71 3.19 ± 0.93 3.03 ± 0.73 0.846
BISPHOSPHONATE, N (%)
Risedronate 38 (62.3) 11 (47.8) 2 (2.7) 9 (30.0) <0.001X
Alendronate 2 (3.3) 10 (43.5) 65 (89.0) 13 (43.3) <0.001X
Ibandronate 21 (34.4) 2 (8.7) 6 (8.2) 8 (26.7) 0.001X
BASELINE BMD, MEAN ± SD
Lumbar spine T-score −2.93 ± 0.84 −2.72 ± 1.23 −2.85 ± 0.96 −2.99 ± 0.95 0.737
Femoral neck T-score −2.41 ± 0.72 −2.35 ± 0.85 −2.17 ± 0.79 −2.43 ± 0.71 0.252
BMD AT 1 YEAR, MEAN ± SD
Lumbar spine T-score −2.85 ± 0.86 −2.46 ± 1.26 −2.52 ± 0.98 −2.50 ± 0.99 0.161
Femoral neck T-score −2.44 ± 0.74 −2.28 ± 0.80 −2.11 ± 0.77 −2.29 ± 0.67 0.093
1-YEAR % CHANGE, MEAN ± SD
Lumbar spine BMD 0.71 ± 5.29 3.89 ± 4.13 5.17 ± 4.93 7.42 ± 3.64 <0.001
Femoral neck BMD −2.09 ± 4.74 1.82 ± 3.64 2.21 ± 3.00 4.78 ± 4.58 <0.001
aCumulative dose (mg of prednisolone or its equivalent) during the 1-year interval between BMD tests.
FP value calculated with Fisher’s exact test.
XP value calculated with chi-square test.
BMI, body mass index; RF, rheumatoid factor; anti-CCP Ab, anti-cyclic citrullinated peptide antibody; csDMARDs, conventional synthetic disease-modifying anti-rheumatic drugs; MTX,
methotrexate; HCQ, hydroxychloroquine; SSZ, sulfasalazine; LEF, leflunomide; TAC, tacrolimus; bDMARDs, biologic disease-modifying anti-rheumatic drugs; TNFi, tumor necrosis factor
inhibitor; DAS28-ESR, disease activity score 28-erythrocyte sedimentation rate; BMD, bone mineral density.
DISCUSSION
In this retrospective study, we showed that in RA patients
with osteoporosis who were receiving bisphosphonates, the
supplementation of vitamin D was significantly associated with
a higher increase in lumbar spine and femoral neck BMDs
within 1 year. The mean differences in 1-year % changes in
lumbar spine and femoral neck BMD were the highest in the
≥1,000-IU/day group. Notably, ≥1,000 IU/day of vitamin D
supplementation was associated with a 3.11% (95% CI: 0.86–
5.37%) and 2.50% (95%CI: 0.63–4.36%) higher increase in 1-year
% changes in lumbar spine and femoral neck BMD, respectively,
compared with 800 IU/day of vitamin D supplementation.
This finding has an important clinical implication in that it
indicates that a vitamin D supplementation dose higher than
that recommended in the current GIOP guideline (4) might
be beneficial in terms of improving BMD in RA patients
with osteoporosis.
In previous studies evaluating the effect of vitamin D
supplementation in non-osteoporotic participants, a 1-year %
change in BMD was 1.0–2.5% higher in patients receiving
vitamin D supplementation (400–800 IU/day) than in those
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FIGURE 1 | One year % change in (A), lumbar spine BMD and (B), femoral neck BMD according to the dose of vitamin D supplementation. The whiskers represent
the 10–90 percentile range, and the black dots represent values outside the 10–90 percentile range. *p < 0.05, ***p < 0.001. BMD, bone mineral density.
TABLE 2 | Linear regression model estimates of the effect of vitamin D
supplementation based on 1-year % changes in BMD.
Univariable analysis Multivariable analysisa
β (95% CI) P β (95% CI) P
LUMBAR SPINE
0 IU/day 0 (ref.) 0 (ref.)
400 IU/day 3.18 (0.87–5.49) 0.007 2.51 (0.04–4.99) 0.047
800 IU/day 4.46 (2.82–6.10) <0.001 2.90 (0.47–5.33) 0.020
≥1,000 IU/day 6.71 (4.61–8.82) <0.001 6.01 (3.71–8.32) <0.001
FEMORAL NECK
0 IU/day 0 (ref.) 0 (ref.)
400 IU/day 3.92 (1.99–5.84) <0.001 3.88 (1.83–5.94) <0.001
800 IU/day 4.30 (2.94–5.67) <0.001 4.30 (2.25–6.35) <0.001
≥1,000 IU/day 6.88 (5.12–8.63) <0.001 6.79 (4.87–8.71) <0.001
aMultivariable model adjusted for age, sex, BMI, total glucocorticoid dose prior to the initial
BMD test, cumulative glucocorticoid dose between BMD tests, use of csDMARDs and
bDMARDs, DAS28-ESR, and type of bisphosphonate.
receiving placebo (17–19). The observed mean difference in 1-
year % change in BMD between the ≥1000-IU/day group and
the 0-IU/day group in our study was remarkably higher (6.01 and
6.79% in the lumbar spine and femoral neck BMD, respectively).
Even in the comparison between the 400-IU/day group and the
0-IU/day group, the mean difference in 1-year % change in BMD
was 2.51% and 3.88% in the lumbar spine and femoral neck BMD,
respectively. The relatively higher mean difference in 1-year %
change in BMD by vitamin D supplementation observed in our
data is likely because we only included patients with osteoporosis,
whereas the previous studies have included participants who
did not present with osteoporosis and the effect of vitamin D
supplementation was assessed for preventive measure in these
studies (17–19). Moreover, patients not receiving vitamin D
supplementation also did not receive calcium supplementation,
TABLE 3 | Linear regression model estimates of the difference in 1-year %
changes in BMD between the ≥1,000- and 800-IU/day groups.
Univariable analysis Multivariable analysisa
β (95% CI) P β (95% CI) P
LUMBAR SPINE
800 IU/day 0 (ref.) 0 (ref.)
≥1,000 IU/day 2.25 (0.21–4.30) 0.031 3.11 (0.86–5.37) 0.007
FEMORAL NECK
800 IU/day 0 (ref.) 0 (ref.)
≥1,000 IU/day 2.57 (0.87–4.27) 0.003 2.50 (0.63–4.36) 0.009
aMultivariable model adjusted for age, sex, BMI, total glucocorticoid dose prior to the initial
BMD test, cumulative glucocorticoid dose between BMD tests, use of csDMARDs and
bDMARDs, DAS28-ESR, and type of bisphosphonate.
which may also explain the higher magnitude of 1-year % change
in BMD in our study.
In vitamin D deficiency, 1, 25-(OH)-vitamin D interacts with
receptors in the osteoblasts, thereby leading to the increased
formation of osteoclasts (20). The mature osteoclast then
releases enzymes to break down the bone matrix, ultimately
releasing calcium and other minerals into the circulation (21).
Therefore, vitamin D supplementation is important in the
treatment of osteoporosis (22). The higher increase in BMD
observed in patients receiving a vitamin D supplementation
dose higher than the dose (600–800 IU/day) recommended
in the general osteoporosis patients might be attributable to
the fact that patients with RA have a higher prevalence and
more severe degree of vitamin D deficiency than the general
population (9, 10, 23).
A previous study has shown that in trials in which a mean
25-(OH)-vitamin D level of 100 nmol/L was achieved, optimal
prevention of osteoporotic fracture was observed (22). In studies
in which baseline 25-(OH)-vitamin D levels were between 40 and
77 nmol/L, patients achieved a 25-(OH)-vitamin D level of 100
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nmol/L with the supplementation of vitamin D at a dose of 700–
800 IU/day (18, 24), whereas in studies in which the baseline
levels were as low as 21–26 nmol/L, patients failed to achieve a 25-
(OH)-vitamin D level of 100 nmol/L with the supplementation of
vitaminD at a dose of 800 IU/day (19, 25). These findings support
the notion that patients with vitamin D deficiency, such as those
with RA, may benefit from a vitamin D supplementation dose
higher than 800 IU/day to improve BMD. Moreover, considering
that vitamin D deficiency is inversely associated with the disease
activity of RA (9, 10), vitamin D supplementation at a higher
dose might be beneficial in improving not only BMD but also
the disease activity of RA. However, as vitamin D intoxication
can result in the mobilization of skeletal calcium, leading to
bone demineralization (26), increasing the dose of vitamin D
supplementation indefinitely cannot be advocated. The suggested
upper limit of vitamin D intake is 4,000 IU/day (6).
Treatment of RA may affect BMD in RA patients with
osteoporosis (27–29). Use of glucocorticoid is associated with
reduction in BMD (27), while use of tumor necrosis factor
inhibitors is associated with increase in BMD in RA patients (28).
Similarly, in our multivariable analysis, use of tumor necrosis
factor inhibitor was associated with a higher increase of 1-year
% change in lumbar spine BMD (β = 2.89 [95% CI: 0.93–4.85],
p = 0.004), while the cumulative glucocorticoid dose between
BMD tests was associated with a lower increase of 1-year %
change in femoral neck BMD (β = −0.001 [95% CI: −0.002
to −0.001], p = 0.001) (Supplementary Table 1). In regard to
csDMARDs, leflunomide may possibly be associated with an
increase in lumbar spine BMD (29). In the present study, use
of leflunomide had a positive effect on lumbar spine BMD (β =
1.02) as well, although it failed to reach statistical significance
(95% CI: −1.01 to 3.04, p = 0.324) (Supplementary Table 1).
We presume that this is because the outcome parameter was
used as a continuous variable in the present study whereas in the
previous study the outcome parameter was used as a categorical
variable (29).
The present study had some limitations. First, this was a
retrospective study, and data about the lifestyle habits of each
patient, such as diet, alcohol intake, and exercise, were not
available. The risk of confounding caused by these undetermined
variables might exist. Further, due to the nonrandomized
retrospective group allocation, possibility of selection bias cannot
be excluded. Second, data about vitamin D levels were missing.
Owing to the lack of these data, the proportion of patients
with vitamin D deficiency at baseline was not identified and
whether patients who are not deficient in vitamin D will also
benefit from a higher dose of vitamin D supplementation was
not evaluated. Third, although we found that ≥1,000 IU/day
of vitamin D supplementation was associated with a higher
increase in 1-year % change in BMD than 800 IU/day of
supplementation, we were unable to determine the optimal dose
of vitamin D supplementation because only a small fraction of
patients received a dose of more than 1,000 IU/day. Further study
investigating the optimal dose of supplementation of vitamin
D, probably over 1,000 IU/day, is needed. Fourth, although we
adjusted for the type of bisphosphonate in the multivariable
analysis, bias which results from the higher use of risedronate in
the 0-IU/day group and higher use of alendronate in the 400, 800,
and ≥1,000-IU/day group cannot be fully adjusted.
In conclusion, we observed a significantly higher increase
in lumbar spine and femoral neck BMD in 1 year in RA
patients with osteoporosis receiving vitamin D supplementation
compared with those who did not. The increase in BMD was the
highest in patients who received a vitamin D supplementation
dose of ≥1,000 IU/day. Our finding suggests that RA patients
with osteoporosis who are receiving bisphosphonate may benefit
more when a higher dose of vitamin D is supplemented than
patients with osteoporosis in the general population.
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